Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2853. doi: 10.1073/pnas.1505059112. Epub 2015 May 4. No abstract available.

2.

Novel recurrently mutated genes in African American colon cancers.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1149-54. doi: 10.1073/pnas.1417064112. Epub 2015 Jan 12.

3.

On systems and control approaches to therapeutic gain.

Radivoyevitch T, Loparo KA, Jackson RC, Sedwick WD.

BMC Cancer. 2006 Apr 25;6:104.

4.

A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage.

Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, Boothman DA.

Oncogene. 2003 Oct 20;22(47):7376-88. Review.

PMID:
14576845
5.

Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.

Yan T, Schupp JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, Veigl ML, Sedwick WD, Boothman DA, Kinsella TJ.

Cancer Res. 2001 Nov 15;61(22):8290-7.

6.

Mismatch repair and drug responses in cancer.

Sedwick WD, Markowitz SD, Veigl ML.

Drug Resist Updat. 1999 Oct;2(5):295-306.

PMID:
11504504
7.

Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability.

Ma AH, Xia L, Littman SJ, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L, Lutterbaugh J, Modrich P, Veigl ML, Markowitz SD, Sedwick WD.

Oncogene. 2000 Apr 27;19(18):2249-56.

8.

Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells.

Chen WD, Eshleman JR, Aminoshariae MR, Ma AH, Veloso N, Markowitz SD, Sedwick WD, Veigl ML.

J Natl Cancer Inst. 2000 Mar 15;92(6):480-5.

PMID:
10716966
9.

Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702.

10.

Increased transversions in a novel mutator colon cancer cell line.

Eshleman JR, Donover PS, Littman SJ, Swinler SE, Li GM, Lutterbaugh JD, Willson JK, Modrich P, Sedwick WD, Markowitz SD, Veigl ML.

Oncogene. 1998 Mar 5;16(9):1125-30.

11.

Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability.

Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longley M, Modrich P, Veigl ML, Sedwick WD.

Oncogene. 1996 Apr 4;12(7):1425-32.

PMID:
8622858
12.

Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.

Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, Veigl ML, Sedwick WD, Markowitz SD.

Oncogene. 1995 Jan 5;10(1):33-7.

PMID:
7824277
13.
14.

Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli.

Sedwick WD, Anderson RD, Baxter J, Donover S, Schneiter S, Veigl ML.

Mutat Res. 1995 Jan;326(1):17-27.

PMID:
7528882
15.

Molecular analysis of hypoxanthine phosphoribosyltransferase gene deletions induced by alpha- and X-radiation in human lymphoblastoid cells.

Bao CY, Ma AH, Evans HH, Horng MF, Mencl J, Hui TE, Sedwick WD.

Mutat Res. 1995 Jan;326(1):1-15.

PMID:
7528877
16.

Excision repair reduces doxorubicin-induced genotoxicity.

Anderson RD, Veigl ML, Baxter J, Sedwick WD.

Mutat Res. 1993 Oct;294(3):215-22.

PMID:
7692261
17.

Sequencing of double-stranded polymerase chain reaction products for mutation analysis.

Anderson RD, Bao CY, Minnick DT, Baxter J, Veigl ML, Sedwick WD.

Mutat Res. 1993 Jul;288(1):181-5.

PMID:
7686261
18.
19.

Mutational specificity of 1,3-bis-(2-chloroethyl)-1-nitrosourea in a Chinese hamster ovary cell line.

Minnick DT, Veigl ML, Sedwick WD.

Cancer Res. 1992 Sep 1;52(17):4688-95.

20.

DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli.

Anderson RD, Veigl ML, Baxter J, Sedwick WD.

Cancer Res. 1991 Aug 1;51(15):3930-7.

Supplemental Content

Loading ...
Support Center